'Highest risk-highest benefit' strategy: a pragmatic, cost-effective approach to targeting use of PCSK9 inhibitor therapies
Author(s)
Annemans, Lieven
Packard, Chris J
Briggs, Andrew
Ray, Kausik K
Type
Journal Article
Date Issued
2018-07-14
Date Acceptance
2017-11-27
Citation
European Heart Journal, 2018, 39 (27), pp.2546-2550
ISSN
0195-668X
Publisher
Oxford University Press (OUP)
Start Page
2546
End Page
2550
Journal / Book Title
European Heart Journal
Volume
39
Issue
27
Copyright Statement
© The Author(s) 2017. Published by Oxford University Press on behalf of the European Society of Cardiology
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
Identifier
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000439059000008&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202
Subjects
Science & Technology
Life Sciences & Biomedicine
Cardiac & Cardiovascular Systems
Cardiovascular System & Cardiology
ATHEROSCLEROTIC CARDIOVASCULAR-DISEASE
SECONDARY-PREVENTION
REDUCING LIPIDS
EVOLOCUMAB
EFFICACY
EVENTS
SAFETY
EZETIMIBE
Publication Status
Published
Date Publish Online
2017-12-11